Healthcare
AstraZeneca and Oracle launch AI collaboration for clinical trials
AstraZeneca and Oracle launched an AI collaboration whose first program will target uncontrolled hypertension and clinical-trial recruitment in Abu Dhabi with M42.
AstraZeneca and Oracle announced a global collaboration combining AstraZeneca’s scientific, clinical-development, and regulatory expertise with Oracle’s real-world data, cloud infrastructure, and AI capabilities. The work will address clinical-trial recruitment, earlier disease diagnosis, drug-safety monitoring, and use of real-world evidence. The collaboration covers oncology, cardiovascular, renal and metabolic, respiratory, immunology, and rare diseases. Its first program will launch in Abu Dhabi with M42 and focus on identifying patients with uncontrolled hypertension, supporting guideline-based treatment, and improving clinical-trial recruitment. The Abu Dhabi deployment is relevant to the GCC because it connects AI-enabled clinical research with local patient-care pathways and a specific population-health priority. The broader initiative is planned across the United States, Middle East, and Europe, suggesting a model in which cloud-based data and AI tools support both research and care delivery. The source describes the partnership’s objectives and initial Abu Dhabi program but does not provide outcome data or confirm deployment beyond the planned initiative.
Original source: RTTNews